Polyrizon Ltd.

Polyrizon Ltd. is an Israel-based, pre-clinical-stage biotechnology company specializing in the development of innovative medical device hydrogels delivered as nasal sprays. The company's core mission is to develop intranasal protective solutions that form a thin, hydrogel-based shield containment barrier in the nasal cavity. Polyrizon Ltd. maintains its headquarters in Raanana, Israel.

Polyrizon's technology is built upon two primary platforms: "Capture and Contain™" (C&C) and "Trap and Target™" (T&T). The C&C platform utilizes hydrogel technology in nasal sprays to create a physical barrier against viruses and allergens, effectively acting as a "biological mask" within the nasal cavity. The T&T platform, currently in pre-clinical development, aims to enhance the intranasal delivery of active pharmaceutical ingredients (APIs) by prolonging their residence time and ensuring close contact with mucosal tissues. Notable product candidates include PL-14 Allergy Blocker, designed for allergic rhinitis, and PL-16 Viral Blocker, developed to offer protection against respiratory viruses such as influenza.

In recent developments, Polyrizon completed a $3.5 million registered direct offering and private placement in April 2026. The company also filed a European patent application for its Trap & Target drug delivery platform in April 2026, complementing a recently announced U.S. patent application that covers both C&C and T&T technologies. A significant manufacturing upscaling milestone for its PL-14 nasal spray was achieved in December 2025, transitioning to larger-scale production to support upcoming clinical trials. Tomer Izraeli serves as the Chief Executive Officer, a role he has held since March 2020, following an earlier tenure from 2005 to 2013. Polyrizon Ltd. is publicly traded on The Nasdaq Capital Market under the ticker symbol PLRZ.